U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07400341) titled 'Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA' on Jan. 19.
Brief Summary: This study is for adults aged 18-65 with myelodysplastic syndrome (MDS) or severe aplastic anemia (AA) who are scheduled to receive a donor stem cell transplant (allogeneic hematopoietic stem cell transplant). After the transplant, it is critical for the body to start making its own blood cells again. A common and serious problem is a delay in the recovery of platelets (the cells that help stop bleeding), which increases the risk of bleeding, infection, and death.
This study aims to see if a new treatment can help platelets ...